Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax, Inc. 2026 Q3 - Results - Earnings Call Presentation
B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16
Novavax (NVAX) reports earnings tomorrow: what to expect
Novavax (NVAX) Q3 2026 Earnings Call Transcript
Novavax Raises FY26 Revenue Outlook By 50% – Retail Says Licensing Deals Could Create ‘Tremendous Financial Leverage’
Novavax (NASDAQ:NVAX) Q3 2026 Revenue Beats Estimates but Shares Slip on Sales Decline
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax: Q3 Earnings Snapshot
Novavax Exec Says Co Is Exploring An Over 50% Reduction To Operating Footprint Via Consolidation Of Buildings And Laboratories; Says Co Expects To Be In A Position To Further Decrease Total Spend To Reach Its 2028 Lean Operating Model Target; Says Co Anticipates Having Less Than Half The Headcount As Compared To Q1 2026
Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
What Novavax Doubters Overlooked
Is Novavax (NVAX) Fully Priced Relative To Its Sales Base?
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.